| Field | Specification |
|---|---|
| Target | |
| Alternative names | Peroxisome proliferator-activated receptor alpha; PPAR-alpha; Nuclear receptor subfamily 1 group C member 1; PPARA; NR1C1; PPAR |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human PPAR alpha/PPARA recombinant protein (Position: M1-L426). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes peroxisome proliferator-activated receptor alpha (gene PPARA) in human, mouse and rat samples and is validated for Western blot, flow cytometry and ELISA. The predicted molecular weight is 52.2 kDa, and the supplier reports an observed band at about 52 kDa.
PPARα (PPARA) is a ligand-activated nuclear receptor that pairs with RXR to control genes of fatty acid uptake and oxidation. It is highly expressed in liver, heart and muscle and is activated by fatty acids and fibrate drugs. PPARα drives the fasting response by switching tissues toward fat burning and is a key target in lipid metabolism research.
| Target | Peroxisome proliferator-activated receptor alpha (gene PPARA; UniProt Q07869, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 52.2 kDa |
| Observed MW | 52 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HepG2 cells, human HeLa cells, human MCF-7 cells, rat liver tissue, mouse liver tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with a confirmed signal (flow cytometry): HepG2 cells.
Immunogen
Recombinant human PPAR alpha/PPARA fragment (Met1–Leu426), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places peroxisome proliferator-activated receptor alpha in the nucleus. Tissue expression noted by UniProt (human): Skeletal muscle, liver, heart and kidney. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Shaohui You et al. (2026) Mucin alleviates HFD-induced obesity and MASLD via an Akkermansia muciniphila-associated mucin-Neu5Ac-PPARα signaling axis. Pharmacological Research. 10.1016/j.phrs.2026.108174
Hai-Yan Ni et al. (2022) Seed oil of Rosa roxburghii Tratt against non-alcoholic fatty liver disease in vivo and in vitro through PPARα/PGC-1α-mediated mitochondrial oxidative metabolism. Phytomedicine. 10.1016/j.phymed.2021.153919
Xu Shi et al. (2024) TIR8 Protects Against Nonalcoholic Steatohepatitis by Antagonizing Lipotoxicity-induced PPARα Downregulation and Reducing the Sensitivity of Hepatocytes to LPS. Translational Research. 10.1016/j.trsl.2024.06.002
Shuai Wang et al. (2025) Camel-Milk-Derived Extracellular Vesicles Mitigate High-Fat-Diet-Induced Obesity by Enhancing Thermogenesis and Modulating Lipid Metabolism in Mice. Journal of Agricultural and Food Chemistry. 10.1021/acs.jafc.5c02577
Yuelei Hu et al. (2026) Targeting Egfr-Mediated Cell Proliferation and Lipid Metabolism Separation Effectively Accelerate Liver Regeneration. Cell Proliferation. 10.1111/cpr.70214
Xiaowei Bao et al. (2026) Sea Buckthorn Pericarp Flavonoids Improve Diet-Induced Hyperlipidemia via Coordinated Modulation of Hepatic Lipid Metabolism and Gut Microbiota. Foods. 10.3390/foods15061049
Linli Gan et al. (2024) Alkaline Mineral Complex Water Attenuates Transportation-Induced Hepatic Lipid Metabolism Dysregulation by AMPKα-SREBP-1c/PPARα Pathways. International Journal of Molecular Sciences. 10.3390/ijms252111373
Kexin Xiao et al. (2024) Protective effects and mechanism of Sangyu granule on acetaminophen-induced liver injury in mice. Journal of Ethnopharmacology. 10.1016/j.jep.2024.118282
Yu Wang et al. (2025) Targeting inflammation and necroptosis in diabetic kidney disease: A novel approach via PPARα modulation. International Immunopharmacology. 10.1016/j.intimp.2025.114562
Li Zhaoyi et al. (2024) Puerarin ameliorates non-alcoholic fatty liver disease by inhibiting lipid metabolism through FMO5. Frontiers in Pharmacology. 10.3389/fphar.2024.1423634
